Wir sind mit live! Mehr erfahren

RxSight

RXST

Börsenwert 188 Mio. $

4,51 USD

-0,16

3,43 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

4,51

0,00

0 %

1 Tag

-3,43 %

5 Tage

-7,01 %

1 Monat

-16,48 %

3 Monate

-19,03 %

6 Monate

-38,89 %

Seit Jahresbeginn

-56,55 %

1 Jahr

-46,82 %

5 Jahre

-64,01 %

10 Jahre

-71,81 %

Profil: RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.

Mitarbeiter: 461

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 12,5 %

Neutral 75 %

Negativ 12,5 %

K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world

K2 Vision has performed 5,000+ Light Adjustable Lens procedures and is recognized by RxSight as the highest-volume LAL practice in the world. Learn more.

K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript

RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript

RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript

RxSight Q2 Earnings Call Highlights

RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.

RxSight Q2 Earnings Call Highlights

Zacks Investment Research

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

RxSight, Inc. (RXST) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.08 per share a year ago.

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook.

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

Zacks Investment Research

Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight's common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138 shares of RxSight's common stock to Aziz Mottiwala, RxSight's new President and Chief Executive Officer in connection with his commencement of employment with RxSight.

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Zacks Investment Research

RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?

RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer.

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt